Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
A “fairly shocking and certainly ironic twist of fate” is ending Sarepta Therapeutics’ CEO Doug Ingram’s nearly decade-long tenure at the helm of the gene therapy maker, he said on an investor call. The executive will retire by the end of 2026 to spend time with his family in the wake of two close family members being diagnosed with myotonic dystrophy.
Resonate Group, an ambitious Nigerian indigenous company with global aspirations, that aligns her vision with strategic intent to provide innovative solutions and services in Oil & Gas, Maritime, Manufacturing, Finance, Steel, Healthcare, and Supply Chain sectors of the Nigerian economy...
